Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InflaRx ( (IFRX) ) has issued an update.
On May 6, 2026, InflaRx announced a strategic focus on developing its oral C5a receptor inhibitor izicopan for ANCA-associated vasculitis, a life-threatening kidney disorder, with Phase 2 planning under way and multiple development paths being evaluated amid a shifting regulatory backdrop for comparator drug avacopan. The company also signaled that it will pursue rapid proof of concept for izicopan in additional complement-mediated renal diseases, including atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy, supported by a planned pharmacokinetic bridging study in China.
InflaRx expects open-label renal studies to start generating clinical data next year and estimates that its current cash will fund planned izicopan programs, key proof-of-concept and Phase 2 readouts, and ongoing operations through 2029, strengthening its financial runway for execution. Management is preparing a summer 2026 Capital Markets Day and maintaining active partnership discussions, while keeping hidradenitis suppurativa on the agenda as a large, partner-dependent opportunity, underscoring izicopan’s central role in the company’s medium-term growth strategy.
The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held back primarily by very weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn), partially offset by a relatively low-debt balance sheet. Technicals are supportive due to strong upward momentum, but overbought signals add near-term risk, while valuation is difficult to support given negative earnings and no dividend data.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V., based in Jena, Germany, is a Nasdaq-listed biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a/C5aR axis. Its lead program is izicopan, an oral C5a receptor inhibitor for inflammatory and renal diseases, alongside vilobelimab, an intravenous anti-C5a antibody that has shown disease-modifying activity in multiple clinical studies.
Founded in 2007, InflaRx uses proprietary anti-C5a and anti-C5aR technologies to discover and commercialize highly potent and specific complement inhibitors. The group operates through offices in Germany and the U.S., focusing on serious, often life-threatening inflammatory indications with substantial unmet medical need and significant commercial potential.
Average Trading Volume: 741,262
Technical Sentiment Signal: Buy
Current Market Cap: $154M
For a thorough assessment of IFRX stock, go to TipRanks’ Stock Analysis page.